Parsaclisib is a small molecule commercialized by Incyte, with a leading Phase II program in Relapsed Chronic Lymphocytic Leukemia (CLL). According to Globaldata, it is involved in 32 clinical trials, of which 16 were completed, 9 are ongoing, 3 are planned, and 4 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Parsaclisib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Go deeper with GlobalData
The revenue for Parsaclisib is expected to reach an annual total of $57 mn by 2033 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Parsaclisib Overview
Parsaclisib is under development for the treatment of indolent/aggressive B-cell non-Hodgkin's lymphoma, mantle cell lymphoma, hairy cell leukemia, Waldenstrom macroglobulinemia, Hodgkin's lymphoma, follicular lymphoma, relapsed/refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma, salivary gland cancer, marginal zone lymphoma including extranodal, nodal, and splenic subtypes, newly diagnosed triple negative breast cancer, and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and autoimmune hemolytic anemia. It is a small molecule administered orally in the form of tablet. It acts by targeting phosphoinositide 3-kinase delta (PI3Kdelta).
The therapeutic candidate was also under development for HER2-positive breast cancer, endometrial cancer, gastric cancer, small cell lung cancer, triple negative breast cancer, ureter cancer, bladder, urethral cancer, head and neck cancer squamous cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, triple-negative breast cancer, transitional cell carcinoma, pemphigus vulgaris and Sjogren's syndrome. It was under development for the treatment of relapsed and refractory diffuse large B-cell lymphoma, peripheral t-cell lymphoma, including peripheral t-cell lymphoma, unspecified type, anaplastic large cell lymphoma (ALK negative or positive), angioimmunoblastic T-cell lymphoma, enteropathy related T-cell lymphoma, hepatosplenic T-cell lymphoma, γ/δ T-cell lymphoma, NK/T-cell lymphoma.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIncyte Overview
Incyte is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.
The company reported revenues of (US Dollars) US$3,394.6 million for the fiscal year ended December 2022 (FY2022), an increase of 13.7% over FY2021. In FY2022, the company’s operating margin was 17.1%, compared to an operating margin of 19.6% in FY2021. In FY2022, the company recorded a net margin of 10%, compared to a net margin of 31.8% in FY2021.
The company reported revenues of US$954.6 million for the second quarter ended June 2023, an increase of 18% over the previous quarter.
For a complete picture of Parsaclisib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
